Cybin Inc. (NEO: CYBN) Acquisition, Three-Pillar Approach Reason for Optimistic MDD Outlook
NEW YORK, Dec. 17, 2020 (GLOBE NEWSWIRE) -- via InvestorWire — Cybin Inc. (NEO: CYBN) today announces its placement in...
Staff
Brain Scientific To Enter the U.S. Pediatric Market with NeuroCap™ for Children
The New Product Offering will Bring Advanced, Disposable EEG Technology to Pediatric Clinicians across the CountryNEW YORK, Dec. 17, 2020...
Acer Therapeutics Announces Publication of Vascular Ehlers-Danlos Syndrome (vEDS) Patient Registry Data from Sweden
Authors report that celiprolol may have a protective effect in COL3A1-positive vEDS patients European Journal of Vascular and Endovascular Surgery:...
American Cannabis Company, Inc. Announces Executed Non-Binding Letter of Intent (LOI) for Strategic Acquisition in Southern Colorado
DENVER, CO, Dec. 17, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- American Cannabis Company, Inc. (OTCQB: AMMJ) (“ACC” or “Company”),...
BeyondSpring Announces the Appointment of Dr. Jeffrey Vacirca to its Board of Directors
NEW YORK, Dec. 17, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused...
SELLAS Strengthens Year-End Balance Sheet with Addition of Approximately $30.5 Million
- Proceeds Received from Registered Direct Offering, Warrant Exercises and Upfront Fee from China Out-licensing - - Improved Cash Position...
BioCardia Announces Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Heart Failure Study as Designed
SAN CARLOS, Calif., Dec. 17, 2020 (GLOBE NEWSWIRE) -- BioCardia (Nasdaq: BCDA), a leader in the development of comprehensive solutions...
Spero Therapeutics Announces Appointment of Sath Shukla as Chief Financial Officer
CAMBRIDGE, Mass., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying,...
CalciMedica Announces IDMC Recommendation to Continue with Trial Evaluating Auxora™ in Patients with Severe COVID-19 Pneumonia
Blinded placebo-controlled trial is expected to enroll more than 100 patients at U.S. clinical sites by end of DecemberThe Company...
VYNE Therapeutics Reports Successful End-of-Phase 2 Meeting with the FDA for FCD105 in Acne
Company on track to initiate the TRILOGY Phase 3 program in 2021BRIDGEWATER, N.J., Dec. 17, 2020 (GLOBE NEWSWIRE) -- VYNE...
Algernon Pharmaceuticals Provides Additional Information on Phase 2b/3 Ifenprodil COVID-19 Study Interim Data
VANCOUVER, British Columbia, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or...
Mersana Therapeutics to Host Virtual Analyst and Investor Event
CAMBRIDGE, Mass., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and...
Eton Pharmaceuticals Announces Acceptance for Filing of New Drug Application for Topiramate Oral Solution
Application Assigned a PDUFA Date of August 6, 2021DEER PARK, Ill., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc....
ORYZON Launches Pioneering Schizophrenia Precision Medicine Study In Collaboration With Columbia Psychiatry
Goal is to characterize the neuropsychiatric symptoms of patients harboring disease-causing SETD1A gene mutationsAlso includes fundamental research in preclinical SETD1A...
Nemaura Medical Launches BEAT®diabetes Program and Its Novel proBEAT™ Non-Invasive, Daily-Wear Adhesive Glucose Monitor
LOUGHBOROUGH, England, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology...
Merus and Sema4 Enter Into an Agreement to Support Merus’ Phase 1/2 Clinical Trial of Zenocutuzumab
UTRECHT, The Netherlands and STAMFORD, Conn., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company...
Aligos Therapeutics Presents Update on Development of SARS-CoV-2 Therapeutic Candidate and Screening Method in Collaboration with KU Leuven at RespiDART & Emerging Viruses 2020
SOUTH SAN FRANCISCO, Calif., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company...
Albireo Initiates Global Phase 3 Clinical Trial of Odevixibat in Alagille Syndrome
- Study represents Albireo’s third global, Phase 3 trial in rare cholestatic liver diseases - - ASSERT gold standard study...
Keros Therapeutics Appoints Mary Ann Gray, Ph.D., to its Board of Directors
LEXINGTON, Mass., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical...
Histogen Announces Filing an Investigational New Drug Application for HST-003
Phase 1/2 Trial Initiation for Knee Cartilage Regeneration Anticipated in First Quarter 2021 $2M Grant Awarded by the Department of...